2,3-Dihydroxybutanedioic acid--(10-methoxy-1,6-dimethylergolin-8-yl)methyl 5-bromopyridine-3-carboxylate (1/1) | 32222-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,3-Dihydroxybutanedioic acid--(10-methoxy-1,6-dimethylergolin-8-yl)methyl 5-bromopyridine-3-carboxylate (1/1)
• 英文别名: [(6aR,9R,10aR)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate;(3R)-2,3-dihydroxybutanedioic acid
• CAS: 32222-75-6
• 化学式: C28H32BrN3O9
• 分子量: 634.5
• InChiKey: HPTSPLOLRPLNPI-PPOPTZJYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.13
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  176
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS
  申请人：Braincells, Inc.

  公开号：EP1991212A1

  公开（公告）日：2008-11-19
• PSYCHO-PHARMACEUTICALS
  申请人：University College Dublin National University Of Ireland, Dublin

  公开号：EP2288345B1

  公开（公告）日：2015-06-10
• [EN] MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS<br/>[FR] MODULATION DE NEUROGENÈSE PAR DES AGENTS NOOTROPES
  申请人：BRAINCELLS INC

  公开号：WO2007104035A1

  公开（公告）日：2007-09-13

  [EN] The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.
  [FR] La présente invention concerne des procédés de traitement de maladies et de conditions pathologiques du système nerveux central et périphérique par la stimulation ou l'accroissement de la neurogenèse. L'invention concerne des compositions et des procédés reposant sur l'utilisation de la mélatonine et d'autre agent nootrope, éventuellement en combinaison avec un ou plusieurs agents neurogènes, pour stimuler ou activer la formation de nouvelles cellules nerveuses.
• [EN] PSYCHO-PHARMACEUTICALS<br/>[FR] PRODUITS PSYCHO-PHARMACEUTIQUES
  申请人：UNIV DUBLIN

  公开号：WO2009128058A1

  公开（公告）日：2009-10-22

  The invention provides a compound for use in the treatment of symptoms associated with psychosis, schizophrenia, a cognitive impairment disorder, a mood disorder, a nervous system disorder and/or a behavioral disorder. The compound has the formula ? and is administered to a subject in need thereof in an effective amount. The compound Meparfynol (3-methylpent-l-yn-3-ol) has been found to be effective.